CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) —
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that
Dr. Klaus Paulini
, Chief Executive Officer
of Aeterna Zentaris, will present at the virtual
H.C. Wainwright
Bio
C
onnect
Conference
taking place January 10-13, 2022.
A
video webcast
of the presentation will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be accessible on the
Events
page in the
Investors
section of the Company’s website (
www.zentaris.com
). The webcast replay will be archived for 90 days following the event.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin (Macrilen
™
), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson’s disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and chlamydia.
For more information, please visit
www.zentaris.com
and connect with the Company on
Twitter
,
LinkedIn
and
Facebook
.
Investor Contact:
Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E:
[email protected]
